Unsurprisingly, Novartis does not want to discuss its pricing strategy for the heart failure treatment LCZ696. However, with the drug having recently delivered compelling Phase III data at the European Cardiology Society (ECS) Congress, it appears that how Novartis chooses to set the cost of LCZ696 is the key unknown variable as analysts look to model its commercial outlook. As one would expect, analysts have become increasingly bullish about the revenue opportunity for LCZ696 in light of the PARADIGM-HF data. However, peak revenue forecasts of between $5 billion and $8 billion for Novartis’ drug are underscored by the assumption that LCZ696 could command a price of up to $8 per day. A key consideration is whether the impressive data presented by Novartis is sufficient to warrant such a premium over the current $4 per month cost for generic enalapril. More here. (Source: FirstWord Pharma, Sept,2014).
You are here: / / Pricing strategy at heart of the matter for Novartis’ LCZ696